Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced on Dec 12, 2025 that Nasdaq notified the company on Dec 10, 2025 it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule requiring at least $2,500,000 in stockholders' equity. The notice follows Clearmind's Form 6-K filed Dec 5, 2025. Nasdaq said it will continue to monitor the company's compliance and warned that if Clearmind does not demonstrate compliance at its next periodic report, it may be subject to delisting. The company remains a clinical-stage biotech developing neuroplastogen-derived therapeutics.
Positive
- Regained compliance with Nasdaq Rule 5550(b)(1) on Dec 10, 2025
- Meets the $2,500,000 minimum stockholders' equity threshold
Negative
- Nasdaq will monitor compliance and noncompliance could trigger delisting
Key Figures
Market Reality Check
Peers on Argus
Within Biotechnology, peers show mixed moves: several names (e.g., SXTP, TTNP, KTTA, SILO) are down while PLRZ is up 13.7%. With no peers in momentum scanners and CMND-specific Nasdaq compliance news, trading appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Reverse share split | Negative | -6.1% | 1-for-40 reverse split to help regain Nasdaq minimum bid price compliance. |
| Dec 05 | Nasdaq bid notice | Negative | +2.5% | Nasdaq notified company of noncompliance with $1.00 minimum bid price rule. |
| Dec 02 | Clinical trial dosing | Positive | -9.9% | First participant dosed in Phase I/IIa CMND-100 trial for alcohol use disorder. |
| Dec 01 | Clinical milestones | Positive | -6.9% | Positive cohort data and DSMB approval plus new elite site joining trial. |
| Nov 25 | Site enrollment | Positive | -19.4% | First patient enrollment at new site in Phase I/IIa CMND-100 AUD trial. |
Recent history shows frequent divergence: positive clinical and listing-related updates often coincided with negative price reactions, while a Nasdaq noncompliance notice saw a modest gain.
Over the past few weeks, Clearmind reported multiple clinical milestones for CMND-100, including positive safety data and new trial sites, yet shares fell after each update. At the same time, the company pursued several financings and corporate actions, such as a 1-for-40 reverse split effective Dec 15, 2025, to address Nasdaq listing rules and stockholders’ equity deficiencies. Today’s announcement that CMND regained compliance with Nasdaq’s $2,500,000 minimum stockholders’ equity requirement follows these capital raises and governance steps.
Market Pulse Summary
This announcement confirms that Clearmind regained compliance with Nasdaq’s $2,500,000 minimum stockholders’ equity requirement, reducing near-term delisting risk tied to equity levels. The move follows multiple registered offerings and a 1-for-40 reverse split aimed at shoring up the balance sheet and listing status. Investors may monitor future periodic reports to see if equity remains above the threshold, alongside ongoing financing activity and clinical trial progress for CMND-100.
Key Terms
form 6-k regulatory
AI-generated analysis. Not financial advice.
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company’s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”), which requires listed companies to maintain stockholders’ equity of at least
Nasdaq has informed the Company that it will continue to monitor the Company’s compliance with the Minimum Stockholders’ Equity Rule. If, at the time of the Company’s next periodic report, the Company does not demonstrate compliance with this requirement, the Company may be subject to delisting.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company’s ability to maintain compliance Nasdaq Listing Rules. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on Dec 12, 2025 about Nasdaq compliance?
Which Nasdaq rule did Clearmind (CMND) regain compliance with and what is the threshold?
When did Nasdaq notify Clearmind (CMND) that it regained compliance?
Does Clearmind (CMND) face any ongoing risk after regaining compliance?
How does this Nasdaq notice affect Clearmind's stockholders?
